BackgroundThe incidence of electrical storm (ES) has been increasing with the rise of the indicated uses of implantable cardioverter defibrillators (ICDs). It is estimated that 20% of patients will evolve to have this complication. Ablative therapy stands out as the treatment for this condition when it is refractory to antiarrhythmic treatment. The objective was to define the current role of catheter ablation in the treatment of electrical storm.MethodsAn integrative literature review was performed using the PubMed and BVS databases. All identified articles were screened and verified for eligibility by the authors.ResultsTwenty-five out of the initial 951 articles were used in the final analysis. The categories listed for analysis included indication for ablation in ES, modality of the approach, therapeutic success, complications related to the procedure, mortality and cardiovascular follow-up and alternative therapeutic modalities by frequency of these categories in the articles researched.ConclusionCatheter ablation is the initial therapy for patients with ischemic cardiomyopathy (ICM) and ES. The endocardial approach presents more relevant success rates than the other therapeutic methods presented.
Introdução: O tratamento de distúrbios na condução atrioventricular associados a doenças do nó sinusal com o emprego de marcapassos DDDR tem incentivado a procura de um sensor ideal. Objetivo: Avaliar a resposta de freqüência do marcapasso com sensor de contratilidade em situações de esforço físico e mental, tanto em laboratório como em atividades diárias de pacientes com bradicardia e insuficiência cronotrópica. Casuística e Métodos: Do estudo multicêntrico brasileiro "Projeto Inos DR _ Brasil", que emprega um sistema de estimulação DDDR cujo indicador é o estado contrátil do miocárdio, foram selecionados 38 pacientes com insuficiência cronotrópica, sendo 21 do sexo masculino e 17 do sexo feminino, com idades variando de 13 a 83 anos (média de 57 anos). O marcapasso utiliza um parâmetro do próprio controle cardiovascular (contratilidade cardíaca obtida pela medida da impedância cardíaca unipolar) para a adaptação da freqüência cardíaca, num sistema de malha fechada que, teoricamente, possibilita um ajuste a todas as necessidades fisiológicas. A calibração e programação do sistema só foi realizada 30 dias após o implante (tempo de maturação da irterface coração-eletrodo), realizando-se, então, teste de estresse mental (matemático) e teste ergométrico (em esteira), monitorados com histograma de freqüência e com curvas de consumo de oxigênio. Resultados: A média de limiares agudos de estimulação foi de 0,82 Volts e 0,55 Volts, e a média de limiares de sensibilidade foi de 2,37 mV e 10,61 mV, respectivamente, para átrios e ventrículos. A média de limiares crônicos de estimulação foi de 1,44 Volts e 1,18 Volts, e a média de limiares de sensibilidade foi de 2,81 mV e 6,3 mV, respectivamente para átrios e ventrículos. A freqüência cardíaca variou de 5% a 128% nas atividades físicas e de 5% a 80% nas atividades mentais, com elevação logo no início das atividades, permitindo uma curva normal de consumo de oxigênio, comparável à de indivíduos normais de mesma faixa etária, sexo e peso. As médias foram comparadas pelo teste T de Student e as variáveis, pela análise de variância. Conclusão: O sensor de contratilidade cardíaca tem excelente desempenho na adaptação da freqüência cardíaca, com valor semelhante ao produzido pelo sistema nervoso autônomo de indivíduos normais.
Introduction: The treatment of AV conduction disorders associated with sinus node illness employing DDDR pacemakers, has motivated the surch for an ideal sensor. Objective: Evaluate the heart rate response of the contractility sensor pacemaker both during the physical effort and mental stress of daily life in out patient tests for patients with bradycardia and chronotropic incompetence. Material and Methods: We use the brazilian Multicentric Study "Inos DR Project _ Brazil" working with a DDDR stimulation system which uses the myocardial contractility state chronotropic 38 patients presenting; incompetence were selected, 21 men and 17 women, with age ranging from 13 to 83 years (mean 57 years). The pacemaker utilizes intrinsic cardiovascular information...
IntroductionIn the last two decades, the increased number of implants of cardiac implantable electronic devices has been accompanied by an increase in complications, especially infection. Current recommendations for the appropriate treatment of cardiac implantable electronic devices-related infections consist of prolonged antibiotic therapy associated with complete device extraction. The purpose of this study was to analyze the importance of percutaneous extraction in the treatment of these devices infections.MethodsA systematic review search was performed in the PubMed, BVS, Cochrane CENTRAL, CAPES, SciELO and ScienceDirect databases. A total of 1,717 studies were identified and subsequently selected according to the eligibility criteria defined by relevance tests by two authors working independently.ResultsSixteen studies, describing a total of 3,354 patients, were selected. Percutaneous extraction was performed in 3,081 patients. The average success rate for the complete percutaneous removal of infected devices was 92.4%. Regarding the procedure, the incidence of major complications was 2.9%, and the incidence of minor complications was 8.4%. The average in-hospital mortality of the patients was 5.4%, and the mortality related to the procedure ranged from 0.4 to 3.6%. The mean mortality was 20% after 6 months and 14% after a one-year follow-up.ConclusionPercutaneous extraction is the main technique for the removal of infected cardiac implantable electronic devices, and it presents low rates of complications and mortality related to the procedure.
Densidade das arritmias supraventriculares e ventriculares em pacientes com síndrome metabólicaDensity of supraventricular and ventricular arrhythmias in patients with metabolic syndrome Densidad de arritmias supraventriculares y ventriculares en pacientes con síndrome metabólico
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.